Diagnostic assays for anti-PM/Scl IgG antibodies: heterogeneity in antibody response or lack of standardization?

[1]  A. Doria,et al.  Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. , 2010, Rheumatology.

[2]  D. Huscher,et al.  Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients , 2009, Arthritis research & therapy.

[3]  M. Fritzler,et al.  Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes , 2007, Arthritis research & therapy.

[4]  E. Chan,et al.  Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. , 2006, Arthritis and rheumatism.

[5]  D. Adoue,et al.  Autoanticorps anti-PM-Scl. Étude de prévalence et de signification , 2006 .

[6]  J. Sibilia,et al.  Anti-pm/scl antibodies in connective tissue disease: Clinical and biological assessment of 14 patients. , 2006, Clinical and experimental rheumatology.

[7]  R. Raijmakers,et al.  Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen , 2005, Arthritis research & therapy.

[8]  G. Pruijn,et al.  PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome. , 2004, Arthritis and rheumatism.

[9]  R Hal Scofield,et al.  Development of autoantibodies before the clinical onset of systemic lupus erythematosus. , 2003, The New England journal of medicine.

[10]  J. Reveille,et al.  The clinical relevance of autoantibodies in scleroderma , 2003, Arthritis research & therapy.

[11]  G. Pruijn,et al.  Autoantibodies directed to novel components of the PM/Scl complex, the human exosome , 2001, Arthritis research.

[12]  D. Isenberg,et al.  Autoantibody profiles in the sera of European patients with myositis , 2001, Annals of the rheumatic diseases.

[13]  I. Hausmanowa-Petrusewicz,et al.  Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. , 1997, Arthritis and rheumatism.

[14]  N. McHugh,et al.  Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. , 1997, The Journal of rheumatology.

[15]  D. Altman,et al.  Statistics notes: Cronbach's alpha , 1997 .

[16]  M. Reichlin,et al.  Anti-PM/Scl autoantibodies in patients without clinical polymyositis or scleroderma. , 1996, The Journal of rheumatology.

[17]  M. Walport,et al.  The Clinical and Immunogenetic Features of Patients with Autoantibodies to the Nucleolar Antigen PM-Scl , 1992, Medicine.

[18]  M. Trucco,et al.  Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. , 1992, Arthritis and rheumatism.

[19]  M. Blüthner,et al.  Cloning and characterization of the cDNA coding for a polymyositis- scleroderma overlap syndrome-related nucleolar 100-kD protein , 1992, The Journal of experimental medicine.

[20]  E. Chan,et al.  Molecular characterization of an autoantigen of PM-Scl in the polymyositis/scleroderma overlap syndrome: a unique and complete human cDNA encoding an apparent 75-kD acidic protein of the nucleolar complex , 1991, The Journal of experimental medicine.

[21]  J. Rodríguez-Sánchez,et al.  Identification of protein components reactive with anti‐PM/Scl autoantibodies , 1990, Clinical and experimental immunology.

[22]  G. Reimer,et al.  Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes. , 1986, Journal of immunology.

[23]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[24]  T. Bunch,et al.  Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes , 2004, Journal of Clinical Immunology.

[25]  M. Kuwana,et al.  Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. , 1994, Arthritis and rheumatism.